Incidence of depression and anxiety among women newly diagnosed with breast or genital organ cancer in Germany

Jacob, Louis; Kalder, Matthias; Kostev, Karel

doi:10.1002/pon.4328

Cited by 31 publications

(15 citation statements)

References 32 publications

(43 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“… 12 – 14 The therapeutic approach to breast cancer is based on a large body of evidence, 15 – 18 and there is increasing interest but still very limited data regarding attending psychiatric diseases in female patients with gynecologic, genital, and cervical cancer. 19 – 21 Patients suffering from different types of gynecologic cancer (genital/cervical cancer) may also have an increased risk of developing an attending psychiatric disease, but little is known about attending psychiatric disorders in patients with cancers other than breast cancer, such as gynecologic cancer.…”

Section: Introductionmentioning

confidence: 99%

Concomitant psychiatric symptoms and impaired quality of life in women with cervical cancer: a critical review

Klügel¹,

Lücke²,

Meta³

et al. 2017

IJWH

View full text Add to dashboard Cite

Our aim was to summarize the current relevant literature on concomitant psychiatric symptoms with a focus on anxiety/depression in a population with gynecologic cancer; to identify the predictors, associated factors, and prevention strategies of psychiatric disorders; to examine psychiatric disorders in a population with recurrent gynecologic cancer; and to describe the limitations of the literature and future research areas. Little is known about attending psychiatric disorders in patients with gynecologic and other malignant diseases like cervical or breast cancer. However, patients suffering from other types of gynecologic cancer (eg, genital/cervical cancer) may also have an increased risk of psychiatric symptoms. In this review, we identify the potential information deficits in this field. A two-rater independent literature search was conducted using the PubMed/Google Scholar search engines to systematically evaluate the literature on the research objectives, followed by a critical reflection on the results. Of the 77 screened studies, 15 met the criteria for inclusion in this review. Patients with gynecologic malignancies, especially cervical cancer, had a very high prevalence of psychiatric symptoms including depression (33%–52%). Additionally, the risk groups facing higher rates of concomitant reduced quality of life and increased psychiatric symptoms such as depression were identified. Specifically, low socioeconomic status, sexual inactivity, absence of a partner, and physical symptoms were correlated with an increased risk. Patients suffering from recurrent gynecologic cancer should receive particular attention because of their significantly increased risk of depressive symptoms. Screening programs are needed to detect psychiatric symptoms in cervical cancer patients and the associated high-risk groups. Regular screening should be implemented, and psychosocial care should be provided during follow-up.

show abstract

Section: Introductionmentioning

confidence: 99%

Concomitant psychiatric symptoms and impaired quality of life in women with cervical cancer: a critical review

Klügel¹,

Lücke²,

Meta³

et al. 2017

IJWH

View full text Add to dashboard Cite

show abstract

“…In a study including 29366 patients with breast and gynecological cancers and investigating the incidence of depression/anxiety in patients, depression incidence was found to be 8.8% and 5.9% respectively in patients with breast and gynecological cancer and it was demonstrated that the risk of depression was 1,41 fold higher in patients with breast cancer than those with gynecological cancer. In the same study, it was stated that the risk of depression was 1.40 times higher in patients with metastasis than those with metastasis (24). In a retrospective study with 1101 patients investigating the relation between depression, disease stage and mortality in patients with prostate cancer, depression was found to be more common in patients with metastasis than those who are in early/local advanced stage.…”

Section: Discusssionmentioning

confidence: 93%

Investigation Of The Severity Of Depressive Symptoms In Cancer Patients Receiving Chemotherapy

Eren¹,

Imamoğlu²,

Karaçin³

et al. 2019

Eastern J Med

View full text Add to dashboard Cite

“…Using prescription statistics for several drugs and age groups for several diagnoses, the Disease Analyzer database was found to be a representative database of clinical practices in Germany [ 15 ]. Finally, several studies focusing on female cancers and using the same database have already been published [ 16 , 17 ].…”

Section: Methodsmentioning

confidence: 99%

Potential delay in the diagnosis of vulvar cancer and associated risk factors in women treated in German gynecological practices

et al. 2018

Self Cite

View full text Add to dashboard Cite

The goal of this study was to estimate a potential delay in the diagnosis of vulvar cancer and identify associated risk factors in women treated in gynecological practices in Germany. The current study sample included 1,652 women from 218 gynecological practices who received an initial diagnosis of vulvar cancer (ICD 10: C51) between January 2000 and December 2015 (index date). After applying several exclusion criteria, 505 non-cancer controls were matched (1:1) to 505 vulvar cancer cases based on age, health insurance status, and index date. The primary outcome was the delay in vulvar cancer diagnosis in women who had received an initial diagnosis of diseases of Bartholin's gland, inflammation of vagina and vulva, or other specified noninflammatory disorders of vulva, including atrophy, hypertrophy, and cyst. A logistic regression model was used to estimate the association between vulvar cancer and pre-defined diagnoses. The mean age was 60.8 years (SD = 15.6 years), and 4.8% of women had private health insurance coverage. Inflammation of vagina and vulva was diagnosed 328 days (SD = 95 days) prior to the detection of vulvar cancer. This delay was 186 days (SD = 196 days) in patients affected by diseases of Bartholin’s gland and 300 days (SD = 116 days) in those with other specified noninflammatory disorders of vulva including atrophy, hypertrophy, and cyst. The risk of vulvar cancer was positively associated with inflammation of vagina and vulva (OR = 2.28) and other specified noninflammatory disorders of vulva (OR = 5.39). The mean potential delay of vulvar cancer diagnosis ranged from 186 to 328 days.

show abstract

Incidence of depression and anxiety among women newly diagnosed with breast or genital organ cancer in Germany

Abstract: Women diagnosed with BC were at a higher risk of developing depression or anxiety than women with GOC.

Cited by 31 publications

References 32 publications

Concomitant psychiatric symptoms and impaired quality of life in women with cervical cancer: a critical review

Concomitant psychiatric symptoms and impaired quality of life in women with cervical cancer: a critical review

Investigation Of The Severity Of Depressive Symptoms In Cancer Patients Receiving Chemotherapy

Potential delay in the diagnosis of vulvar cancer and associated risk factors in women treated in German gynecological practices

Contact Info

Product

Resources

About